Clearbridge Investments LLC Has $1.33 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Clearbridge Investments LLC cut its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 98.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,420 shares of the company's stock after selling 4,656,428 shares during the quarter. Clearbridge Investments LLC's holdings in Kenvue were worth $1,333,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares during the last quarter. State Street Corp raised its stake in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Geode Capital Management LLC raised its holdings in shares of Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock valued at $1,029,810,000 after purchasing an additional 399,846 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Kenvue by 2.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company's stock valued at $533,169,000 after purchasing an additional 561,570 shares during the period. Finally, Norges Bank bought a new position in shares of Kenvue in the fourth quarter worth $521,348,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Remove Ads

Kenvue Stock Down 5.5 %

Shares of NYSE KVUE traded down $1.29 during midday trading on Friday, hitting $22.33. The company's stock had a trading volume of 17,763,957 shares, compared to its average volume of 16,812,043. The business's fifty day simple moving average is $22.59 and its two-hundred day simple moving average is $22.46. The firm has a market capitalization of $42.68 billion, a price-to-earnings ratio of 42.14, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KVUE. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Barclays boosted their target price on shares of Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Kenvue has an average rating of "Hold" and an average price target of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.